Champions Oncology, Inc. (CSBR)

In the past six months, Champions Oncology's stock experienced several notable events. In Q1 Fiscal Year 2026, the company reported $14 million in revenue with a slight decline in service revenue but an increase in data license revenue. In Q4 Fiscal Year 2025, Champions Oncology announced record annual revenue of $57 million. In Q3 Fiscal Year 2025, total revenue increased by 42% to $17.0 million, with the signing of a data licensing deal worth up to $8.0 million. In Q2 Fiscal Year 2025, the company reported revenue of $13.5 million, a 17% increase over the same period last year. The stock price increased by 27% in the month leading up to September 16, 2025, and was up 66% over the last year, but had fallen by -2.40% in the last week and -3.70% in the last month as of November 26, 2025. An independent director exercised options to buy stock on November 7, 2025.

Specific seasonal fluctuations in demand for Champions Oncology's products and services are not explicitly detailed, but the market for its core offerings demonstrates strong underlying growth. The patient-derived xenograft (PDX) model market is experiencing robust growth, projected to reach US$1,119.36 million by 2031. The company anticipates continued topline expansion and margin improvement driven by a healthy services pipeline and growing demand for its proprietary data offerings. Intellectia AI suggests that buying CSBR stock in June has the highest probability of a positive return, while October has the lowest.

Champions Oncology, Inc. is a technology-enabled research organization focused on accelerating oncology drug development and personalizing cancer care. The company's core business provides advanced technology solutions and products for oncology drug discovery and development. Their offerings include the TumorGraft Technology Platform, Translational Oncology Solutions (TOS), Personalized Oncology Solutions (POS), Lumin Bioinformatics, and a Radiopharmaceutical Services Platform.

Champions Oncology, Inc. is headquartered in Hackensack, New Jersey, USA, with additional offices in Rockville, Maryland, USA; Rehovot, Israel; and Milan, Italy. The company has a global reach with clinical sites, laboratories, and a scientific team distributed worldwide to support international studies.

Explicit information about Champions Oncology's brand reputation is not readily available. The company emphasizes scientific excellence and a culture of collaboration. MarketBeat's MarketRank™ scored Champions Oncology higher than 58% of companies evaluated in the medical sector, suggesting a generally favorable perception within its industry.

Champions Oncology, Inc. has a mixed ownership structure. Institutional investors own approximately 32.40% to 41.87% of the outstanding shares, with major shareholders including Battery Management Corp., NEA Management Company, LLC, and Vanguard Group Inc. Insiders, including executives and board members, hold a substantial portion of the company, ranging up to 46.98%, with Michael Maurice Brown being the largest individual shareholder.